Skip to content
Home/Companies/Biotech/Syndivia
Syndivia

Syndivia

Biotech·France·Active·7yr hold
Entry
2019
Hold
7yr
Status
Active

Who owns Syndivia?

Syndivia is a French Biotech company, currently owned by Capital Grand Est since 2019.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Capital Grand Est
Investor
Capital Grand Est
Cap Innov'Est 1 · 2014 · VC

Key facts

HQFrance
SectorBiotech
Websitewww.syndivia.com

More from Cap Innov'Est 1

Other portfolio companies in the same fund.

AdipoPharma
AdipoPharma
Active
PharmaFrance
Synovo
Synovo
Exited
Business ServicesFrance
to Jérémy Wies, Michel Lacombe and Guillaume Philipp
Urania Therapeutics
Active
BiotechFrance· 2020
TSA Industrie
TSA Industrie
Exited 2025
IndustrialsFrance· 2018
to Turenne Groupe
Exeliom Biosciences
Exeliom Biosciences
Active
BiotechFrance· 2017
HipTest
Exited 2018
TMTFrance· 2016
to SmartBear Software

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Syndivia?

Syndivia is currently owned by Capital Grand Est, through Cap Innov'Est 1, since 2019.

When did Capital Grand Est acquire Syndivia?

Capital Grand Est acquired Syndivia in 2019.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue